Why TRT Raised Your Blood Pressure (and How to Fix It)

Your cardiovascular system is a pressure system, and pressure systems have rules. When you add testosterone to the equation, you are not just changing your hormones, you are changing the physical properties of the fluid running through that system and the volume of that fluid and the capacity of the vessels handling it. Blood pressure goes up on TRT when any one of those three things gets out of balance, and it goes down when all three are managed. That is the whole framework. Everything else is detail inside that framework.

Start with the fluid itself.

Testosterone tells your bone marrow to make more red blood cells, and it does this in a direct, dose-dependent way, meaning the more testosterone you take the more your body responds. A study measuring hemoglobin and hematocrit across graded testosterone doses confirmed the relationship is essentially linear. Your hematocrit is something called a measure of blood thickness, specifically the percentage of your blood volume that is occupied by red blood cells rather than plasma. When that percentage climbs, your blood gets physically harder to push through your vessels, and your heart has to generate more pressure to do it.

Think of it like trying to pump honey versus water through the same set of pipes. The pipes did not change. The pump did not change. The resistance went up because the fluid changed.

A randomized controlled trial measuring this directly found that men whose hematocrit rose more than 6% on testosterone therapy saw their systolic blood pressure increase by 13.2 millimeters of mercury compared to placebo. That is a clinically meaningful number. It is the kind of number that moves someone from one blood pressure category into another. And the mechanism is straightforward: thicker blood, more vascular resistance, higher pressure.

The clinical threshold that most endocrinology guidelines treat as the action point is a hematocrit of 54%. Above that number, the downstream risks, including stroke and cardiovascular events, shift in a direction that requires a response. That response is either a dose adjustment or a pause in therapy, not something to manage around indefinitely.

This is why checking hematocrit every six months on TRT is not optional monitoring. It is the feedback mechanism that tells you whether your dose is creating a problem in the fluid itself.

Now move to the second lever, which is where a lot of protocols quietly make things worse.

When your body receives exogenous testosterone, some of it converts into estradiol through a process called aromatization, which is just the name for the enzymatic conversion that happens primarily in fat tissue. Estradiol then acts on the kidneys and promotes something called sodium retention, which is exactly what it sounds like, your kidneys hold onto sodium instead of filtering it out, and water follows sodium, so your blood volume expands. More volume in the same vessel space means more pressure.

That part most people on TRT have heard. What they do not hear as often is what happens when you try to suppress that estradiol with an aromatase inhibitor and you overcorrect.

Estradiol is not just a side effect of TRT. It is active in your cardiovascular system. It supports endothelial function, which is the health of the inner lining of your blood vessels, and it has vasodilatory effects, meaning it helps vessels stay relaxed and open. When you block aromatization too aggressively and crash your estradiol, you lose that protection. Research in animal models blocking aromatase showed increases in mean arterial pressure and markers of kidney injury, which points to the same mechanism running in reverse: less estradiol, worse vascular function, higher pressure.

So the picture is not just "high estradiol raises blood pressure." It is "estradiol outside a functional range in either direction creates cardiovascular problems." The target most clinicians use is somewhere between 20 and 40 picograms per milliliter on a sensitive assay, not a standard one, because standard estradiol tests are calibrated for female ranges and are not sensitive enough to read male physiology accurately.

The way to stay in that range is by adjusting injection frequency before reaching for an aromatase inhibitor. More frequent, smaller injections produce a steadier testosterone level, which means less of a spike in conversion, which means less estradiol fluctuation. An aromatase inhibitor is a blunt instrument. Injection frequency is a dial. Use the dial first.

The third lever is the one that has nothing to do with your bloodwork at all.

Testosterone increases blood volume directly, not just through red blood cell production but through its effects on fluid handling in the kidney. Research measuring extracellular water in men on testosterone therapy found increases independent of other hormones, which means testosterone itself is expanding the space your cardiovascular system has to manage. That is not a problem if your cardiovascular system is adapting to it. It is a problem if it is not.

The adaptation that handles increased blood volume is cardiac output capacity, which is the ability of your heart to move more blood per minute without increasing pressure. That capacity comes from cardiovascular training. When you do sustained aerobic work regularly, your heart becomes more efficient, your vessels become more compliant, and your body gets better at distributing volume without raising pressure to compensate.

Without that adaptation, the increased volume just presses harder against the same unimproved system.

This is why cardio is not a lifestyle recommendation layered on top of TRT. It is mechanistically connected to how your cardiovascular system handles what TRT does to your blood volume. They are linked. Removing the cardio removes the adaptive capacity.

When all three of these are managed, hematocrit below 54%, estradiol in the 20 to 40 range, and the cardiovascular system actively adapting through aerobic training, TRT does not raise blood pressure. In a study of 737 hypogonadal men on long-term testosterone therapy, men who were not on blood pressure medication saw their systolic pressure drop by approximately 12.5 millimeters of mercury. In a separate cohort of 202 men on antihypertensives, 33 of them were able to discontinue their medication entirely while on TRT.

The mechanism there is also real. Testosterone in physiological range supports nitric oxide production, reduces inflammatory markers in vessel walls, and improves body composition in ways that independently lower cardiovascular load.

The problem was never testosterone. The problem is that most protocols monitor testosterone and ignore everything testosterone does to the system it is running through.

---

References

1. Olesen TB, Glintborg D, Johnk F, et al. 2024. Blood pressure responses to testosterone therapy are amplified by hematocrit levels in opioid-induced androgen deficiency. Journal of Hypertension, 423, 531-540. Finding: Office SBP increased 6.2 mmHg in testosterone group vs 7.0 mmHg decrease in placebo net 13.2 mmHg. Men with hematocrit rise >6% saw clinically relevant BP increases. Source
2. Coviello AD, Kaplan B, Lakshman KM, et al. 2008. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. Journal of Clinical Endocrinology and Metabolism, 933, 914-919. Finding: Hemoglobin and hematocrit increased in a linear, dose-dependent fashion. Source
3. Almutlaq RN, Newell-Fugate AE, Evans LC, et al. 2022. Aromatase inhibition increases blood pressure and markers of renal injury in female rats. American Journal of Physiology Renal Physiology, 3232, F170-F181. Finding: Blocking aromatase increased mean arterial pressure. Source
4. Hackett G, Mann A, Haider A, et al. 2024. Testosterone replacement therapy: effects on blood pressure in hypogonadal men. World Journal of Mens Health, 422, 431-443. Finding: Long-term TRT associated with significant SBP and DBP reductions. 33 of 202 men on antihypertensives discontinued them. Source
5. Agrawal P, Singh SM, Kohn T. 2023. Management of erythrocytosis in men receiving testosterone therapy. European Urology Focus, 91, 139-142. Finding: Hematocrit >54% requires dose decrease or discontinuation. Source
6. Johannsson G, Gibney J, Wolthers T, et al. 2005. Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men. Journal of Clinical Endocrinology and Metabolism, 907, 3891-3896. Finding: Testosterone independently increased extracellular water through renal tubule effects. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness